GlassScriptPhysician profile
Michael S Taptykoff
NPI 1245210806
$2,266.34
in general payments reported to CMS, 2019-2025
21 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $128 · 2022: $320 · 2023: $509 · 2024: $437 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $426.78 | 2019-2024 | Airsupra, Farxiga |
| Amgen INC. | $227.52 | 2019-2025 | Evenity, Krystexxa |
| Lilly USA, LLC | $220.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $135.60 | 2019 | |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Zimmer Biomet Holdings, INC. | $124.60 | 2023 | Dvr Anatomic Kickstand |
| Janssen Biotech, INC. | $120.80 | 2025 | Simponi Aria, Tremfya |
| Amarin Pharma, INC. | $108.34 | 2019 | |
| Boston Scientific Corporation | $85.14 | 2023 | Watchman Flx |
| Ani Pharmaceuticals, INC. | $82.68 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $80.64 | 2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $79.52 | 2019-2020 | |
| Vertos Medical, INC. | $77.32 | 2023 | Mild Device Kit |
| Pfizer INC. | $73.40 | 2019-2020 | |
| Glaukos Corporation | $67.30 | 2024 | Idose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.71 | 2019 | |
| Novo Nordisk INC | $41.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.93 | 2019 | |
| Daiichi Sankyo INC. | $22.46 | 2019 | |
| Phadia US INC. | $19.01 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Taptykoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.